✨ Free AI Report
Glaukos Corporation: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Glaukos Corporation
Company Research

Glaukos Corporation: Business Overview, Financials & Competitive Analysis

Glaukos Corporation scores 8/10 on the AskCyborg Cyborg Score (Strong). Market-leading ophthalmic device innovator with triple-digit growth in core glaucoma franchise and expanding portfolio in complementary segments, backed by fortress balance sheet. The company is experiencing exceptional growth with record Q3 2025 net sales of $133.5M (+38% YoY) and U.S. glaucoma sales of $80.8M (+57% YoY). Strong financial health and.

What is Glaukos Corporation's industry? Glaukos Corporation (glaukos.com) operates in Medical Devices & Ophthalmic Pharmaceuticals. AskCyborg classifies Glaukos Corporation under Medical Devices & Ophthalmic Pharmaceuticals in its company registry.

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationall...

8/ 10Strong

Cyborg Score thesis

Market-leading ophthalmic device innovator with triple-digit growth in core glaucoma franchise and expanding portfolio in...

Read the full analyst-debate transcript →
Industry Medical Devices & Ophthalmic Pharmaceuticals
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 5, 2026
AI-Verified Research
30+ Page Report

Get the Latest Glaukos Corporation Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Glaukos Corporation

AskCyborg analysts argue the bull and bear cases for Glaukos Corporation across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Glaukos Corporation OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Glaukos Corporation Overview

Pro stress-test →

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company commands a leadership position in minimally invasive glaucoma surgery with its flagship micro-bypass stent technologies.

Strategic Profile

Pro stress-test →

The company achieved record net sales of $133.5 million in Q3 2025, representing 38% year-over-year growth, demonstrating strong market momentum. Glaukos maintains a strong balance sheet with significant institutional ownership and absence of debt, positioning it for sustained expansion across its glaucoma, corneal disorder, and emerging retinal disease portfolios.

Competitive Landscape

Pro stress-test →

Glaukos competes in the ophthalmic medical device sector against larger diversified medical technology companies including Johnson & Johnson (Accera/JWAK platforms), Bausch + Lomb (glaucoma solutions), and Alcon (traditional and MIGS offerings). The company differentiates through specialized focus on minimally invasive glaucoma surgery and novel dropless delivery platforms.

Industry Context

Glaukos Corporation operates in Medical Devices & Ophthalmic Pharmaceuticals.

Key facts

Founded: 1998 · Headquarters: Aliso Viejo, California · Employees: 995 · Revenue: $383.5M · Market cap: $6.6B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Glaukos Corporation.

  • Company raised 2025 guidance to $490-495M and introduced 2026 guidance of $600-620M in net sales, indicating confidence in continued acceleration
  • Flagship iStent and iStent infinite products treat mild-to-moderate and therapy-resistant glaucoma, complemented by iDose TR intracameral delivery technology
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • September 2025Record Q3 2025 net sales of $133.5M with 38% YoY growth and 45% growth in glaucoma segment
  • December 2025Participated in Citi Annual Global Healthcare Conference
  • +1 moreTrack every material event for Glaukos Corporation as it happens. Explore monitoring →
Get alerted when Glaukos Corporation has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

JWAKGlaucoma management platforms→Glaucoma SolutionsComprehensive glaucoma care portfolio→LenSxFemtosecond laser and ophthalmic platforms→

Compare Glaukos Corporation with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Glaukos Corporation operates in Medical Devices & Ophthalmic Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Medical Devices & Ophthalmic Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Glaukos Corporation

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Glaukos Corporation and its top competitor on Cyborg Score”
“What did Glaukos Corporation do this quarter?”
“Is Glaukos Corporation a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Glaukos Corporation do?+
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationall...
What is Glaukos Corporation's Cyborg Score?+
Glaukos Corporation has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Glaukos Corporation's main competitors?+
Named competitors include JWAK, Glaucoma Solutions, LenSx. The full competitive landscape is in the AskCyborg report.
How can I get the full Glaukos Corporation research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Glaukos Corporation research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Glaukos Corporation over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.